THURSDAY, SEPTEMBER 22

7:00 am  Registration/Continental Breakfast/Exhibits
7:30   Welcome:  Mark S. Blumenkranz, MD, President, The Retina Society
         Monica Varano, MD, President, Società Italiana della Retina
         Mario Stirpe, MD, Co-Chairman, Program

SESSION 1 - RETINAL PHARMACOLOGY: VEGF INHIBITION

Presiding Officer:  Mark S. Blumenkranz, MD
Moderator:   Rosario Brancato, MD

7:30 am Intravitreal Ranibizumab for Vascularized Pigment Epithelium
         Detachment.................................................................Francesco Bandello, MD
7:37 Questions

7:40 High (2.0 MG) versus Conventional-dose (0.5 MG) Ranibizumab for
         Managing Vascularized Pigment Epithelial Detachments Associated with
         Age-related Macular Degeneration.................................Clement K. Chan, MD
7:47 Questions

7:50 Effects of Intravitreal Anti-VEGF Agents on Retinal Morphology, Neovascular
         Network Size and Best Corrected Visual Acuity in Patients with Pigment
         Epithelium Detachment due to Occult Choroidal Neovascularization ..........Daniele Veritti, MD
7:57 Questions

8:00 Correlation of Retinal Morphology and Function Under Anti-VEGF
         Therapy In Patients with Neovascular Age-related Macular
         Degeneration (nAMD)......................................................Ursula Schmidt-Erfurth, MD
8:07 Questions

8:10 Long-term Results of Anti-VEGF Therapy for Choroidal Neovascularization
         Associated with Age-related Macular Degeneration.........................John T. Thompson, MD
8:17 Questions

8:20 Intravitreal Ranibizumab versus Bevacizumab in Choroidal Neovascularization
         in Pathologic Myopia. A Randomized Study ................................Alfredo Pece, MD
8:27 Questions

8:30 Impact of Availability of Anti-VEGF Therapy on Vision Impairment
         and Blindness due to Neovascular Age-related Macular Degeneration.......Susan B. Bressler, MD
8:37 Questions

8:40 Combined Anti-VEGF and Photodynamic Therapy for Treatment of Age-related
         Macular Degeneration Refractory to Anti-VEGF Monotherapy ..........Lawrence P. Chong, MD
8:47 Questions
THURSDAY

8:50 Combined Therapy (Intravitreal Bevacizumab Plus Verteporfin Photodynamic Therapy) versus Intravitreal Bevacizumab Monotherapy for Choroidal Neovascularization Due to Age-related Macular Degeneration. A One-year Follow-up Study .................................................. Sandro Saviano, MD

8:57 Questions

9:00 Dexamethasone Intravitreal Implant Alone and as an Adjunct to Ranibizumab for Treatment of Choroidal Neovascularization Secondary to Age-related Macular Degeneration................................................................. Michael A. Singer, MD

9:07 Questions

9:10 Angiographic Findings Following X-ray Irradiation for Treatment of Wet Age-related Macular Degeneration: 18 Month Follow-up .................... Darius M. Moshfeghi, MD

9:17 Questions

9:20 VEGF Trap-Eye Vs Ranibizumab for Neovascular AMD: Results From 2457 Patients in the Phase 3 VIEW 1 and VIEW 2 Studies ........................................ Jeffrey S. Heier, MD

9:27 Questions

9:30 Asymptomatic Fluid in the Second Eye of Patients with Neovascular Age-related Macular Degeneration: Detection by OCT and Treatment with Anti-VEGF Therapy ............................................................... Lucian V. Del Priore, MD, PhD

9:37 Questions

9:40 REFRESHMENT BREAK/EXHIBITS

SESSION 2 - TREATMENT OF MACULAR EDEMA

Presiding Officer: Julia A. Haller, MD
Moderator: David Boyer, MD

10:10 am VEGF Trap-Eye in Diabetic Macular Edema: One-year Results of the DA VINCI Study ................................................................. W. Lloyd Clark, MD

10:17 Questions

10:20 Ranibizumab (Anti-VEGF) for Vision Loss Due to Diabetic Macular Edema Results of Two Phase III Randomized Trials ......................................... Anthony P. Adamis, MD

10:27 Questions

10:30 Rationale of Diabetic Retinopathy Clinical Research Network Intravitreal Anti-VEGF Treatment and Follow-up of Center-involved Diabetic Macular Edema.............................................................. Lloyd Paul Aiello, MD, PhD

10:37 Questions

10:40 Vision-related Function after Ranibizumab Treatment for Diabetic Macula Edema (DME) by Better- or Worse-Seeing Eyes: Clinical Trial Results from RESTORE, RIDE, and RISE ......................................................... Neil M. Bressler, MD
THURSDAY

10:47 Questions

10:50 To Estimate the Potential Costs and Savings Associated with Intravitreal Ranibizumab with Prompt or Deferred Focal/Grid Laser as Compared with Prompt Focal/Grid Laser for Diabetic Macular Edema (DME).............Scott M. Friedman, MD

10:57 Questions

11:00 Effects of Ranibizumab on Reading Speed Through 24 Months in Patients with Vision Impairment from Diabetic Macular Edema (DME)......................Ivan J. Suner, MD

11:07 Questions

11:10 VEGF Trap-Eye in CRVO: Results from the Phase 3 COPERNICUS Study ......................................................David S. Boyer, MD

11:17 Questions

11:20 Dexamethasone Intravitreal Implant Rapidly Improves Best-Corrected Visual Acuity Within 7 Days in Patients With Retinal Vein Occlusion ..............Julia A. Haller, MD

11:27 Questions

11:30 Patients with Macular Edema Due to Branch Retinal Vein Occlusion Achieve Greater Clinical Benefit from Dexamethasone Intravitreal Implant When Treated Within the First 90 Days Early Following Onset of Macular Edema.........................................................Baruch D. Kuppermann, MD, PhD

11:37 Questions

11:40 Combination Therapy for Diffuse Diabetic Macula Edema (DME)............Keith A. Warren, MD

11:47 Questions

11:50 Functional And Anatomical Response Of Idiopathic Macular Telangiectasis To Intravitreal Anti-Vegf Treatment With Bevacizumab........................Shlomit Schaal MD

11:57 Questions

12:00 Efficacy and Safety Results of Participants Receiving ILUVIEN (Fluocinolone Acetonide) Insert in the FAME Program .....................Rajendra S. Apte, MD, PhD

12:07 Questions

12:10 Clinical Correlation of Wide-angle fluorescein angiography and Retinal Oxymetry Findings in the Treatment Response of Retinal Vein Occlusions .............................................Veronica A. Kon-Jara, MD

12:17 Questions

12:20 Peripheral Polypoidal Choroidal Vasculopathy: A Report of 10 Eyes.................................................................Darin Goldman, MD

12:27 Questions

12:30 – 1:30 LUNCH

1:30-2:00 POSTER VIEWING
### SESSION 3 - RETINAL RESEARCH: THE BENCH

**Presiding Officer:** William F. Mieler, MD  
**Moderator:** Claudio Azzolini, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 pm</td>
<td>Photoreceptor Regeneration in a Swine Model of Retinal Damage</td>
<td>Henry J. Kaplan, MD</td>
</tr>
<tr>
<td>2:07</td>
<td>Questions</td>
<td></td>
</tr>
<tr>
<td>2:10</td>
<td>Long-term Suppression of Ocular Neovascularization with a Single Intravitreal Administration of a Viral Gene Transfer Vector Coding for Bevacizumab</td>
<td>Szilard Kiss, MD</td>
</tr>
<tr>
<td>2:17</td>
<td>Questions</td>
<td></td>
</tr>
<tr>
<td>2:20</td>
<td>Clinicopathologic Features of Epiretinal Proliferation in Familial Exudative Vitreoretinopathy</td>
<td>Sander R. Dubovy, MD</td>
</tr>
<tr>
<td>2:27</td>
<td>Questions</td>
<td></td>
</tr>
<tr>
<td>2:30</td>
<td>Mechanism of Cell Loss in Age-related Macular Degeneration and Retinal Degenerations. A Path to Clinical Trials in Neuroprotection</td>
<td>Demetrios Vavvas MD</td>
</tr>
<tr>
<td>2:37</td>
<td>Questions</td>
<td></td>
</tr>
<tr>
<td>2:40</td>
<td>Role of Fas Signaling in the Retina after Sodium Iodate Mediated Retinal Pigment Epithelium Injury</td>
<td>David N. Zacks, MD, PhD</td>
</tr>
<tr>
<td>2:47</td>
<td>Questions</td>
<td></td>
</tr>
<tr>
<td>2:50</td>
<td>From Muller Glia Cells to Photoreceptors</td>
<td>Claudio Azzolini, MD</td>
</tr>
<tr>
<td>2:57</td>
<td>Questions</td>
<td></td>
</tr>
<tr>
<td>3:00</td>
<td>PLGA Nanospheres Encapsulated within Thermo-responsive Hydrogel for Ocular Delivery of Dexamethasone Sodium Phosphate</td>
<td>William F. Mieler, MD</td>
</tr>
<tr>
<td>3:07</td>
<td>Questions</td>
<td></td>
</tr>
<tr>
<td>3:10</td>
<td>Constellation 2.0: Eliminating Infusion Bubbles and Uncontrolled Reflux</td>
<td>Stephen R. Russell, MD</td>
</tr>
<tr>
<td>3:17</td>
<td>Questions</td>
<td></td>
</tr>
<tr>
<td>3:20</td>
<td>A Cat Model for Chronic Suprachoroidal Electrical Stimulation of the Retina</td>
<td>Penelope J. Allen, FRANZCO</td>
</tr>
<tr>
<td>3:27</td>
<td>Questions</td>
<td></td>
</tr>
</tbody>
</table>

### SESSION 4 - CLINICAL RESEARCH: THE BEDSIDE

**Presiding Officer:** Allen C. Ho, MD  
**Moderator:** Steven D. Schwartz, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30 pm</td>
<td>Ocriplasmin for the Treatment of Symptomatic Vitreomacular Adhesions (sVMA): Results from the MIVI-TRUST Phase III program</td>
<td>Allen C. Ho, MD</td>
</tr>
<tr>
<td>3:37</td>
<td>Questions</td>
<td></td>
</tr>
</tbody>
</table>
THURSDAY

3:40 Ocriplasmin for the Treatment of Macular Holes: Results from the MIVI-TRUST Phase III Program............................... Peter K. Kaiser, MD
3:47 Questions

3:50 Preclinical Rationale and Phase 1 Safety Trial Design for Stem Cell Derived Retinal Pigment Epithelium Therapy for the Treatment of Stargardt and Age Related Macular Degenerations......................................................... Steven D. Schwartz, MD
3:57 Questions

4:00 Phase I Human Safety Study of Integrin Antagonist in Diabetic Retinopathy Subjects ................................................................. Hugo Quiroz-Mercado, MD
4:07 Questions

4:10 Oral Synthetic cis-Retinoid Therapy in Subjects with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) due to Lecithin:Retinol Acyltransferase (LRAT) or Retinal Pigment Epithelial 65 Protein (RPE65) mutations: Preliminary Results of a Phase Ib Open Label Trial.............David A. Saperstein, MD
4:17 Questions

4:20 Randomized, Double-masked, Controlled Translational Investigation of Bevacizumab For Severe Retinal Detachment Due To Proliferative Diabetic Retinopathy: 3 Month Results ..............................................................Elliott Sohn, MD
4:27 Questions

4:30 Effects of Music Therapy on Patients' Anxiety During Intravitreal Injections: A Randomized Clinical Trial.................................................................Ron Adelman, MD
4:37 Questions

4:40 Cytokine Concentration in Aqueous Humor of Eyes with Diabetic Macular Edema .................................................................................Jost B. Jonas, MD
4:47 Questions

4:50 Novel Methods to Enhance Reading Ability in Patients with Macular Disease ..................................................................................Daniel B. Roth, MD
4:57 Questions

5:00 ADJOURN
FRIDAY, SEPTEMBER 23

7:00 am    Registration/Continental Breakfast/Exhibits

SESSION 5 - SURGICAL TECHNIQUES

Presiding Officer:  Mark W. Johnson, MD  
Moderator:  Donald J. D’Amico, MD

7:30 am   Outcomes of Small Incision Vitreoretinal Surgery without Trimming of Vitreous Base for Rhegmatogenous Retinal Detachment..........Homayoun Tabandeh, MD, MS 
7:37      Questions

7:40      Minimalist Pars Plana Vitrectomy for Repair of Primary Rhegmatogenous Retinal Detachment..............................................................Mark W. Johnson, MD 
7:47      Questions

7:50      Pars Plana Vitrectomy Alone after primary Pseudophakic Macula-off Rhegmatogenous Retinal Detachment........................................Vicente Martinez-Castillo, MD 
7:57      Questions

8:00      Continuous Indirect Ophthalmoscope Monitored Drainage of Subretinal Fluid..............................................................................Edwin H. Ryan,MD 
8:07      Questions

8:10      Tamponade Volume, Posterior Pressure, and Trabecular Block in Silicone-Oil-Associated Glaucoma........................Hermann D. Schubert, MD 
8:17      Questions

8:20      Sequential Epiretinal Membrane Removal: Internal Limiting Membrane Pattern ...........................................................................Constantin J. Pournaras, MD 
8:27      Questions

8:30      Intraoperative Ocular Coherence Tomography: Macular Morphology following Posterior Vitreous Separation, ERM and ILM Peeling................Antonio P. Ciardella, MD 
8:37      Questions

8:40      Intrasurgical SD-Optical Coherence Tomography - An Update........Susanne Binder, MD 
9:47      Questions

8:50      Trypan Blue versus Brilliant Blue G in Epiretinal Membrane Surgery .........................................................................................Christiane I. Falkner-Radler, MD 
8:57      Questions

9:00      The Gold Standard of Secondary Intraocular Lens Implantation in the Transconjunctival Era.................................................................Cesare Forlini, MD  
9:07      Questions
FRIDAY

9:10 Vitrectomy and Gas Tamponade with Internal Limiting Membrane Peeling For Myopic Foveoschisis................................................................. Settimio Rossi, MD
9:17 Questions

9:20 The IRISS Ocular Robotic Surgical Platform........................................ Jean-Pierre Hubschman, MD
9:27 Questions

9:30 Polyethylene Glycol (PEG) Hydrogel Polymer Sealant for Sclerotomy Closure: Preliminary in vivo Clinical Results........................................... Fabio Patelli, MD
9:37 Questions

9:40 Coloring of PFCL Facilitates Safe and Efficient Removal of Temporary Tamponades................................................................. Stanislao Rizzo, MD
9:47 Questions

9:50 Evolving Techniques for Silicone Oil Injection, Removal, and Reoperation for Epimacular Membrane (EMM) or Proliferative Vitreoretinopathy (PVR) without Oil Removal.................................................. Steve Charles, MD
9:57 Questions

10:00 Use of HeavySIL 1500, a New Heavier-than-water Endotamponade, in Complicated Retinal Detachment Surgery ....................... Cesare Mariotti, MD
10:07 Questions

10:10 Presence of Residual Perfluorocarbon Liquid and Its Interaction with Heavy Silicone Oil: Risk Factor for Sticky Oil Formation..... Mario R. Romano, MD, PhD
10:17 Questions

10:20 REFRESHMENT BREAK/EXHIBITS

SESSION 6 - AWARD PRESENTATIONS

10:50 – 10:55 Introduction of Michael F. Marmor, MD..................................Mark S. Blumenkranz, MD
RETINA RESEARCH AWARD OF MERIT – CHARLES L. SCHEPENS LECTURE
10:55 – 11:15 The Art of Retina .................................................................Michael F. Marmor, MD

11:15 – 11:20 Introduction of Mario Stirpe ..............................................Donald J. D’Amico MD
5th ANNUAL J. DONALD M. GASS AWARD
11:20 – 11:40 Posterior Staphyloma in High Myopic Eyes: Vitreoretinal Pathology ....Mario Stirpe, MD

11:40-11:45 Introduction of Fellowship Awards ................................. William F. Mieler, MD
11:45 FELLOWSHIP RESEARCH AWARD PRESENTATION
ERK-mediated Activation of Fas Apoptosis Inhibitory Molecule (Faim2)..... Cagri G. Besirli, MD

11:55 RAYMOND R. MARGHERIO AWARD PRESENTATION
A Novel Strategy to Develop Preventative Therapy for Proliferative Vitreoretinopathy ................................. Marc-Andre Rheaume, MD

12:05 ADJOURN
SATURDAY, SEPTEMBER 24

7:00 am Registration/Continental Breakfast/Exhibits

SESSION 7 - TUMORS

Presiding Officer: Timothy G. Murray, MD, MBA
Moderator: Evangelos S. Gragoudas, MD

7:30 am Combined Simultaneous Transpupillary Hyperthermia ICG-assisted Photodynamic Therapy (CSTIP) with Intravitreal Ranibizumab for Small...Peter E. Liggett, MD

7:37 Questions

7:40 Prognostic Significance of GEP Class of Posterior Uveal Melanomas in Prospective Single Center Study........................James J. Augsburger, MD

7:47 Questions

7:50 Paraneoplastic Bilateral Diffuse Uveal Melanocytic Proliferation is Caused by a Factor Found in the IgG Fraction of Serum........................Jose S. Pulido, MD

7:57 Questions

8:00 Optic Nerve Damage after Irradiation of Intracocular Tumors........Evangelos S. Gragoudas

8:07 Questions

8:10 Hemodynamic Modifications of the Retina and Choroid following Proton Beam Irradiation of Uveal Melanomas. Panoramic Fluorescein Angiography and ICG Study ....................................................Leonidas Zografos, MD

8:17 Questions

8:20 Proton Beam Radiation of Choroidal Hemangioma ................Michael H. Foerster, MD, PhD

8:27 Questions

8:30 Intrararterial Chemotherapy for Retinoblastoma Using Routes Other than the Ophthalmic Artery.............................................................David H. Abramson, MD

8:37 Questions

8:40 Intra-arterial Chemotherapeutic Dosing Strategy Directly Impacts Retinoblastoma Tumor Control ...................................................Timothy G. Murray, MD, MBA

8:47 Questions

SESSION 8 - UVEITIS

Presiding Officer: Bernard H. Doft, MD
Moderator: Douglas A. Jabs, MD

8:50 Prophylaxis for Endophthalmitis Associated with Intravitreal Injection: Antisepsis and Antibiotics ......................................................Harry W. Flynn, Jr., MD

8:57 Questions

9:00 Indolent Nonprogressive Multifocal Choroidal Lesions............................Lee M. Jampol, MD
SATURDAY
9:07  Questions

9:10  Standardization of Uveitis Nomenclature: An Informatics Approach to Classification Criteria Development .................................................. Douglas A. Jabs, MD
9:17  Questions

9:20  Cauterization of Leaking Sclerotomies after 23-gauge Transconjunctival Pars Plana Vitrectomy ............................................................... Francesco Boscia, MD
9:27  Questions

9:30  REFRESHMENT BREAK/EXHIBITS

SESSION 9 - PEDIATRIC RETINAL DISEASES AND IMAGING

Presiding Officer: Michael T. Trese, MD
Moderator: Edoardo Midena, MD, PhD

10:00  Evaluation of Plus Disease Progression Using Digital Registration of Multiple Images ................................................................. Jane Myung, MD
10:07  Questions

10:10  Coats' Disease: Unilateral or Bilateral? ...................................................... Audina M. Berrocal, MD
10:17  Questions

10:20  Angiogenesis and Angiomaintenance in Pediatric Retinal Disease .......... Michael T. Trese, MD
10:27  Questions

10:30  Rescued Vascularization by Norrin in a Model of Retinopathy ...... Kimberly A. Drenser, MD, PhD
10:37  Questions

10:40  Release and Velocity of Micronized Dexamethasone Intravitreal Implants with an Intravitreal Drug Delivery System - Kinematic Analysis with a High-speed Camera ......................................................... Carsten H. Meyer, MD
10:47  Questions

10:50  Novel Wide-field Montage Spectral-domain Optical Coherence Tomography Technique in Patients with X-linked Retinoschisis ....................... Ninel Z. Gregori, MD
10:57  Questions

11:00  Grading the Severity of Posterior Staphyloma using SD OCT Imaging and Correlation with Macular Complications Including Macular Schisis and Macular Hole Formation .................................................. David Sarraf, MD
11:07  Questions

11:10  SD-OCT and HD-MRI study of Dome-shaped Macula in Pathologic Myopia ......................................................................................... Giampaolo Amato, MD
11:17  Questions

11:20  Refractive State, Axial Length, and Choroidal Thickness in Central Serous Chorioretinopathy ................................................................. Gaetano R. Barile, MD
SATURDAY

11:27 Questions

11:30 Diabetic Retinopathy Viewed as a Neurodegenerative Disorders:
In vivo Retinal Glial Cells Activation .................................................... Edoardo Midena, MD, PhD
11:37 Questions

11:40 Peripheral Autofluorescence Findings in Age-related Macular
Degeneration............................................................................................ SriniVas R. Sadda, MD
11:47 Questions

11:50 Line Scanning Angiography for Detection of Retinal and Choroidal Disease ... Deeba Husain, MD
11:57 Questions

12:00 ANNUAL BUSINESS MEETING – THE RETINA SOCIETY

1:00 pm ADJOURN
SUNDAY, SEPTEMBER 25

7:00 am Registration/Continental Breakfast/Exhibits

SESSION 10 - IMAGING AND LASERS

Presiding Officer: Thomas R. Friberg, MD
Moderator: Guido Ripandelli, MD

7:30 am Three-Dimensional High-Definition Live Vitreoretinal Surgery Transmission Using Conventional Telecommunication Lines................................. Akitoshi Yoshida, MD, PhD
7:37 Questions

7:40 Incorporation of Telemedicine Diabetic Retinopathy Assessment with a Medicare Quality Improvement Program ............................................ Ingrid E. Zimmer-Galler, MD
7:47 Questions

7:50 Ophthalmicedge.org (Free Ophthalmic Instructional Website): Current Analytics and Phase II Expansion.................................................. Yale L. Fisher, MD
7:57 Questions

8:00 Selective VEGF 165 Blockade can Reverse Retinal Capillary Non-perfusion as Demonstrated on Ultra-wide Angle Angiography...................... Thomas R. Friberg, MD
8:07 Questions

8:10 Assessment of Retinal Non-Perfusion by Calculating an Ischemic Index in Diabetic Retinopathy and Vein Occlusions with Ultra Wide Field Fluorescein Angiography ...................................................... Valentina Franco-Cardenas, MD
8:17 Questions

8:20 Multi-imaging Characteristics of Diabetic Macular Edema ...................... Stela Vujosevic, MD
8:27 Questions

8:30 Fundus Autofluorescence and Microperimetry in Progressing Geographic Atrophy Secondary to Age-related Macular Degeneration.................. Elisabetta Pilotto, MD
8:37 Questions

8:40 577 nm Yellow Selective Subthreshold Laser Photocoagulation for the Treatment of Central Serous Chorioretinopathy with Foveal Leakage .......... Jose A. Cardillo, MD
8:47 Questions

8:50 Subthreshold Micropulse Yellow Laser (577nm) Photocoagulation for Macular Edema (ME) ................................................................. Oh Woong Kwon, MD
8:57 Questions

9:00 New Opportunities for Targeted Retina Therapy using Navigated Laser ......................................................................................... Giovanni Staurenghi, MD
9:07 Questions

9:10 Retinal Navigated Laser (Navilas®) Compared Versus Conventional Laser in Diabetic Macular Edema......................................................... Anselm Kampik, FEBO
9:17 Questions
8:00 Meeting of the Board of Directors
8:30 Last Minute Business
9:00 Opening Remarks
9:05 Welcome Address
9:15 Presentation: The Latest Advances in Ophthalmic Surgery
9:40 Questions
10:00 Refreshment Break
10:15 Presentation: The Role of Artificial Intelligence in Eye Disease Diagnosis
10:45 Questions
11:00 Presentation: The Future of Eye Care: Innovations and Emerging Technologies
11:30 Questions
11:45 Closing Remarks
12:00 Adjournment
SUNDAY

11:30  Posterior Juxtascleral Injection of a Commercially Available Triamcinolone Acetonide Injectable Suspension Plus a Viscoelastic Agent in Refractory Diabetic Macular Edema ................................................................. Paolo Lanzetta, MD

11:37  Questions

11:40  Incidence of Macular Edema in the Multiple Sclerosis Clinical Program of Fingolimod (FTY720) .................................................................................................. Marco A. Zarbin, MD, PhD

11:47  Questions

11:50  DARPin® MP0112 Shows Extended VEGF Inhibition Effect in Diabetic Macular Edema .............................................................................. Brian B. Berger, MD

11:57  Questions

12:00 p.m. Maculopexy (MX) Resolves Diffuse Diabetic Macular Edema ........ Robert E. Morris, MD

12:07  Questions

12:10  Spectral Domain Optical Coherence Tomography and Microperimetry Outcomes after 23 Gauge Vitrectomy for Idiopathic Macular Pucker .. Fabo Scarinici, MD

12:17  Questions

12:20  ADJOURN